SP-40,40 is an 80-kDa glycoprotein consisting of two 40-kDa subunits (a-chain and b-chain). It is a multi-functional protein which modulates the membrane attack complex of the complement, [1] [2] [3] causes cell aggregation, 4) accelerates immune complex formation 5) and binds to b-endorphin.
The induction of SP-40,40 synthesis in the hippocampi of patients with Alzheimer's disease has been reported, 7, 8) and we have also reported the incorporation of SP-40,40 into senile plaque.
9) It was also reported that SP-40,40 existed in serum as a minor component of high density lipoproteins. [10] [11] [12] From its structural similarity, SP-40,40 is thought to be a human counterpart of ram clusterin, which causes cell aggregation, 13) rat SGP-2, which participates in spermatogenesis, 14) rat TRPM-2, which is induced during programmed cell death (apoptosis), 15) quail T64, which is induced by src gene expression, 16) bovine GPIII, which is purified from the chromaffin granule membrane of adrenal medula 17) and canine gp80, which is a marker protein of apical secretion. 18) Plasminogen activator inhibitor-1 (PAI-1) is an unstable protein which binds to plasminogen activator (PA) and inhibits its activity. 19, 20) It was reported that S-protein (vitronectin) bound to PAI-1 and stabilized its activity. 21, 22) Declerck et al. purified PAI-1-binding protein (PAI-1-BP), and it was shown to consist of S-protein and unidentified 40-kDa protein on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) under reducing conditions. 23) From the functional similarity of S-protein and SP-40,40, e.g., inhibition of the complement system [1] [2] [3] and binding to b-endorphin, 6) we supposed that the unidentified 40-kDa protein might be SP-40,40. In this paper, I describe that PAI-1-BP consists of S-protein and SP-40,40, and that SP-40,40 stabilizes PAI-1 activity as well as S-protein does.
MATERIALS AND METHODS
Materials Plasminogen, urine plasminogen activator (uPA) and fibrinogen were purchased from Sigma. Fibrinogen was cleaved with BrCN in 70% formic acid and dialyzed against distilled water as described by Verheijen et al. 24) S-2251 was obtained from Kabi. Recombinant tissue plasminogen activator (tPA) was kindly gifted from Yamanouchi Co., Ltd. Outdated human plasma was obtained from the Japanese Red Cross Tokyo Blood Center, Musashino, Tokyo.
Purification of PAI-1 PAI-1 was purified from the culture medium of HT1080 (human fibrosarcoma cell) according to Andreasen et al. 19) The cells were maintained as a monolayer culture in Dulbecco-modified Eagle's medium (Gibco) supplemented with 10% fetal bovine serum (Gibco) and 1 mM dexamethasone (Sigma). After the cells reached 80% confluence, the medium was changed to serum-free medium containing 1 mM dexamethasone, and the culture was continued for 3 d. PAI-1 (500 mg) was purified from 1 l of the serum-free conditioned medium using a Con A-Sepharose (20 ml, Pharmacia) column. Purified PAI-1 was activated in 12 M urea at 37°C for 30 min and dialyzed against PBS at 4°C overnight. Purification of S-Protein and SP-40,40, and Preparation of Antibodies and Antibody-Conjugated Sepharose S-protein and SP-40,40 were purified by the methods described by Yatohgo et al. 25) and Choi et al., 26) respectively. Antibodies against PAI-1, S-protein and SP-40,40 were obtained from rabbits immunized with 3ϫ100 mg of each protein as an emulsion with Freund's complete adjuvant. IgG was purified from antiserum by ammonium sulfate precipitation and by DEAE-Sephacel chromatography. IgG was coupled to CNBr-activated Sepharose 4B (Pharmacia) according to the manufacturer's instruction.
Purification of PAI-1 · PAI-1-BP Complex PAI-1 · PAI-1-BP complex was purified according to Declerck et al. 23) Human plasma (50 ml) was subjected to gel-filtration with a Bio Gel A-0.5 m (Bio Rad) column (5ϫ85 cm) in phosphatebuffered saline (PBS). Fractions of 7 S globulin were concentrated to 50 ml by ultra-filtration and incubated with 200 mg of activated PAI-1 at 37°C for 10 min. The mixture was subjected to gel-filtration again, as above. The first PAI-1 fraction detected by Western-blot analysis was applied onto an anti-PAI-1-Sepharose (150 mg IgG/30 ml Sepharose) column. The column was washed with 0.5 M NaCl in 10 mM sodium phosphate, pH 7.0, and eluted with 0.2 M glycine-HCl, pH 2.8. The pH of the eluate was adjusted to pH 7.0 with 1 M Tris and concentrated by ultra-filtration.
SDS-PAGE and Western-Blot Analysis Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was performed according to Laemmli. 27) Western-blot analy-sis was performed using a Vectastain kit (Vector) according to the manufacturer's instructions. After electrophoresis, proteins were transferred onto a nitrocellulose filter, and the binding site of the filter was blocked with 3% gelatin in PBS.
The filter was treated with each first antibody, followed by peroxidase-conjugated second antibody. The color was developed with diaminobenzidine and H 2 O 2 . PAI-1•tPA Complex Formation PAI-1 · tPA complex formation was measured by the method of Lindahl et al. 20) Activated PAI-1 (1 mg) was incubated in the presence or absence of SP-40,40 (1 mg) at 37°C for 1 h. Recombinant tPA (1 mg) was added and further incubated at 37°C for 1 h. PAI-1 · tPA complex formation was measured by SDS-PAGE, followed by silver staining (Wako Pure Chemical Ind.).
Assay of PAI-1 Activity PAI-1 activity was measured according to Verheijen et al. 24) and Declerck et al. 23) Briefly, PAI-1, plasminogen, uPA, BrCN-fragments of fibrinogen and S-2251 diluted in 50 mM Tris-HCl, 0.1 M NaCl and 0.01% Tween 80, pH 7.4, were mixed (total volume : 200 ml) in a well of a flat-bottomed 96-well microtiter plate (Nunc). After incubation at 37°C for 1 h, the absorbance was measured using a Titertek multiscan plate reader (Flow Laboratories) at 405 nm.
RESULTS

Presence of SP-40,40 in PAI-1•PAI-1-BP Complex
PAI-1 · PAI-1-BP complex was purified and analyzed on SDS-PAGE (Fig. 1a) . As described previously, 23) thus it revealed two typical bands of S-protein, PAI-1 and unidentified 40-kDa protein under reducing conditions. The 40-kDa protein disappeared on SDS-PAGE under non-reducing conditions, as described previously. 23) SP-40,40 shows an 80-kDa band on SDS-PAGE under non-reducing conditions and 40-kDa band under reducing conditions. The components of the complex were analyzed by Western-blot analysis (Fig. 1b) .
Since anti-SP-40,40 antibody stained the unidentified protein, it was thought that PAI-1-BP consisted of S-protein and SP-40,40. The protein bands which moved at the 220-kDa position seemed to be aggregates of PAI-1, because anti-PAI-1 antibody reacted to them.
Effect of SP-40,40 on PAI-1 · tPA Complex Formation
It is known that active PAI-1 forms a stable complex with plasminogen activator (PA) and inhibits PA activity. 20) After incubation of PAI-1 at 37°C for 1 h, PAI-1 was inactivated and could not form a complex with tPA (Fig. 2) . However, in the presence of SP-40,40, PAI-1 inactivation was suppressed and PAI-1 · tPA complex formation was detected. Therefore, 40 Vol. 24, No. 1
Fig. 1. SDS-PAGE and Western-Blot Analysis of PAI-1 · PAI-1-BP Complex
a) Purified PAI-1 · PAI-1-BP complex (3 mg) was analyzed on SDS-PAGE (10% gel) under reducing conditions. After electrophoresis, proteins were stained with Coomassie brilliant blue R-250. An MW-SDS-200 kit (Sigma) was used to determine the molecular weight. b) After electrophoresis as described above, proteins in the gel were transfered onto a nitrocellulose filter. The filter strips were treated with anti-S-protein, anti-PAI-1 or anti-SP-40,40 antibody and processed as described in MATERIALS AND METHODS. it is evident that SP-40,40 is involved in PAI-1 stabilization.
Assay System for the Measurement of PAI-1 Activity To study the stabilization activity of SP-40,40 for PAI-1, we first titrated uPA in the assay system (Fig. 3a) . From the result, we decided to use a 1/100 dilution of uPA for further assay. Next, we titrated PAI-1 in the assay system (Fig. 3b) . PAI-1 inhibited uPA activity dose-dependently. From the result, we decided to use a 1/4 dilution of PAI-1 for the assay of SP-40,40 activity on PAI-1 stabilization.
Stabilizing Activity of SP-40,40 for PAI-1 It is known that PAI-1 activity decreases rapidly during the incubation at 37°C. 23) I examined the activity of SP-40,40 on the insecurity of PAI-1 (Table I) . After the incubation of PAI-1 at 37°C for 1 h, the activity of PAI-1 decreased to 66% of the original activity. In the presence of SP-40,40, the inactivation of PAI-1 during the incubation at 37°C for 1 h was suppressed as thoroughly as in the presence of S-protein. Then, we titrated the stabilizing activity of SP-40,40 for PAI-1 (Fig. 4) . S-protein and SP-40,40 both suppressed the inactivation of PAI-1 during the incubation at 37°C in a dose-dependent manner. The mixture of S-protein and SP-40,40 stabilized PAI-1 as an additive effect. DISCUSSION SP-40,40 is a multi-functional protein as well as S-protein (vitronectin). The common activities of both proteins include regulation of the membrane attack complex of the complement [28] [29] [30] and binding to b-endorphin. 31, 32) In this paper, I described another common activity of S-protein and SP-40,40 on PAI-1 stabilization. The important finding of these proteins is the presence of a complex of S-protein and SP-40,40.
1) Our results in this paper suggested that PAI-1-BP is a complex of S-protein and SP-40,40. Declerck et al. reported that a PAI-1 · PAI-1-BP complex was 450 kDa on gel-filtration, 23 ) therefore, we calculated that the PAI-1 · PAI-1-BP complex consisted of two molecules each of PAI-1,S-protein and SP-40,40. They also indicated that the complex of PAI-1 and S-protein showed a smaller molecular weight on gel-filtration than that of the PAI-1 · PAI-1-BP complex. This may Ten microliters of PAI-1 (20 mg/ml ) were pre-incubataed with 5 ml each of S-protein (200 mg/ml) and/or SP-40,40 (200 mg/ml) at 37°C for 1 h. Plasminogen, uPA, BrCNfragments of fibrinogen and S-2251 were added to each well, and incubated at 37°C for 1 h, as described in the legend of Fig. 3 . *: control experiment which was not pre-incubated at 37°C for 1 h. % Stabilization of PAI-1 was calculated as [(1.004-A 405 )/ (1.004-0.100)]ϫ100 (%). Ten microliters each of plasminogen (1 mg/ml), BrCN-fragments of fibrinogen (1 mg/ml), S-2251 (12 mM) and diluted uPA (original concentration: 1 u/ml) were mixed and incubated at 37°C for 1 h (final volume: 200 ml with the buffer). The absorbance was measured using a plate reader at 405 nm. b) Titration of PAI-1 for the assay. Ten microliters each of plasminogen, uPA (10 mu/ml), BrCN-fragments of fibrinogen, S2251 and diluted PAI-1 (original concentration : 80 mg/ml) were mixed and incubated as described above. Ten microliters of PAI-1 (20 mg/ml) were pre-incubated with 5 ml each of diluted Sprotein (original concentration: 200 mg/ml) and/or diluted SP-40,40 (original concentration: 200 mg/ml ) at 37°C for 1 h. Plasminogen, uPA, BrCN-fragments of fibrinogen and S-2251 were added to each assay system, and incubated at 37°C for 1 h, as described in the legend of Fig. 3 . % Stabilization of PAI-1 was calculated as described in the legend of Table I. be caused by the deficiency of SP-40,40.
Our binding study indicated that SP-40,40 did not bind to PAI-1 directly (data not shown). Since S-protein binds to PAI-1 directly, 21, 22) it is thought that bindings in PAI-1 · PAI-1-BP are formed between PAI-1 and S-protein and between S-protein and SP-40,40. As shown in Fig. 4 , SP-40,40 stabilized PAI-1 activity more weakly than S-protein did. This result may be due to the lower affinity of SP-40,40 to PAI-1 than that of S-protein.
In this paper, I described that SP-40,40 could be an effector molecule for the regulation of the fibrinolytic system as effectively as S-protein. SP-40,40 and S-protein both also inhibit the complement system. [1] [2] [3] In the coagulation system, S-protein binds to and stabilizes thrombin, 33) but the activity of SP-40,40 on the coagulation system has not been elucidated. The physiological significance of SP-40,40 and S-protein on PAI-1 stabilization should be clarified.
